cisplatin / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

234 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Recruiting
3
165
RoW
tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
Shanghai Kechow Pharma, Inc.
Melanoma
09/27
09/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Recruiting
3
700
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
10/27
12/30
FIGHT-302, NCT03656536 / 2018-002894-23: A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Checkmark From P3 FIGHT-302 trial for 1L cholangiocarcinoma at ESMO-GI 2021
Jun 2021 - Jun 2021: From P3 FIGHT-302 trial for 1L cholangiocarcinoma at ESMO-GI 2021
Checkmark First patient treated in FIGHT-302, P3 trial
Jun 2019 - Jun 2019: First patient treated in FIGHT-302, P3 trial
Recruiting
3
434
Europe, Canada, Japan, US, RoW
Pemigatinib, INCB054828, Gemcitabine, Cisplatin
Incyte Corporation
Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
10/27
07/28
KEYLYNK-013, NCT04624204 / 2019-003616-31: Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/)

Recruiting
3
672
Europe, Canada, Japan, US, RoW
Pembrolizumab 200 mg, MK-3475, KEYTRUDA®, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, MK-7339, LYNPARZA®, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Merck Sharp & Dohme LLC
Small Cell Lung Cancer
10/27
10/27
STAR-121, NCT05502237: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Recruiting
3
720
Europe, Canada, Japan, US, RoW
Zimberelimab, GS-0122, AB122, Domvanalimab, GS-0154, AB154, Pembrolizumab, KEYTRUDA®, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Gilead Sciences, Arcus Biosciences, Inc.
Non-small Cell Lung Cancer
09/27
09/27
AdvanTIG-306, NCT05791097: Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

Withdrawn
3
980
NA
Ociperlimab, WCD118, Placebo, Tislelizumab, VDT482, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
Novartis Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
12/27
12/27
M22-142, NCT06093503: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn
3
250
NA
Telisotuzumab Vedotin, ABBV-399, Osimertinib, Cisplatin, Carboplatin, Pemetrexed
AbbVie
Non-Small Cell Lung Cancer
04/28
04/28
KEYVIBE-006, NCT05298423: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/)

Recruiting
3
784
Europe, Japan, US, RoW
pembrolizumab/vibostolimab, MK-7684A, durvalumab, IMFINZI®, cisplatin, PLATINOL-AQ®, pemetrexed, ALIMTA®, etoposide, TOPOSAR®, carboplatin, PARAPLATIN®, paclitaxel, TAXOL®, thoracic radiotherapy
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
09/28
09/29
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Not yet recruiting
3
632
NA
QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo
Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
10/28
10/31
KEYNOTE-992, NCT04241185 / 2019-004023-20: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/)

Calendar Jan 2026 - Dec 2026: Data from P3 KEYNOTE-992 trial for muscle invasive bladder cancer
Recruiting
3
636
Europe, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab
Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms
06/29
06/31
ARTEMIDE-Bil01, NCT06109779: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
AstraZeneca
Biliary Tract Cancer
06/29
09/30
TRITON, NCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

Recruiting
3
280
US
Durvalumab, Tremelimumab, Pemetrexed, Background Platinum-based Chemotherapy, Pembrolizumab, Carboplatin, Cisplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/27
03/31
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/33
08/38
INDUCE-4, NCT04428333 / 2019-003981-42: Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated
2/3
118
Europe, Canada, Japan, US, RoW
Feladilimab, Pembrolizumab, Placebo, Platinum based chemotherapy, Fluorouracil (5FU)
GlaxoSmithKline, Merck Sharp & Dohme LLC
Neoplasms, Head and Neck
04/21
09/23
NCT04864782: QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Terminated
2/3
46
RoW
QL1604, PD-1 monoclonal antibody, Paclitaxel injection, Cisplatin/Carboplatin
Qilu Pharmaceutical Co., Ltd.
Cervical Cancer
09/22
11/23
NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Recruiting
2/3
700
RoW
HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin
Taizhou Hanzhong biomedical co. LTD
Nonsquamous Non-small Cell Lung Cancer
09/22
09/23
SIRCCA, NCT02807181: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Completed
2/3
89
Europe, US, RoW
Cisplatin-gemcitabine, CIS-GEM, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Sirtex Medical
Intrahepatic Cholangiocarcinoma
10/22
10/22
CA209-6KP, NCT05213312: Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Recruiting
2/3
90
RoW
Nivolumab, Cisplatin, Paclitaxel, 5Fluorouracil, Esophagectomy (minimally invasive)
Shanghai Zhongshan Hospital, Bristol-Myers Squibb
Esophageal Squamous Cell Carcinoma
11/22
03/24
NCT03086993 / 2016-003812-10: Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Active, not recruiting
2/3
295
US
Melphalan/HDS, Melphalan/PHP, Cisplatin and Gemcitabine, Cis/Gem
Delcath Systems Inc.
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
01/23
05/23
NCT03668639: Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Recruiting
2/3
80
Europe
Akynzeo, Dexamethasone
Christina Ruhlmann, Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
03/23
04/23
FUGEN, NCT06105619: A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene ().

Active, not recruiting
2/3
84
RoW
PLB1001, Vebreltinib, Temozolomide, Cisplatin combined with Etoposide
Beijing Pearl Biotechnology Limited Liability Company
Glioblastoma
04/23
12/24
NCT02784171 / 2016-002286-60: Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Active, not recruiting
2/3
520
Europe, Canada
Cisplatin, Pemetrexed, Pembrolizumab
Canadian Cancer Trials Group, National Cancer Institute, Naples, Merck Sharp & Dohme LLC, Intergroupe Francophone de Cancerologie Thoracique
Mesothelioma
04/23
06/24
2022-004130-19: A clinical research study comparing two cisplatin dosing schedules combined with radiation for patients with advanced head and neck cancer.

Not yet recruiting
2/3
1250
Europe
Cisplatin, Concentrate for solution for infusion, Cisplatin
Cancer Trials Ireland, NRG Oncology, National Cancer Institute
Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck (SCCHN) of the oropharynx, larynx, hypopharynx, or p16-positive unknown primary., Advanced head and neck cancer., Diseases [C] - Cancer [C04]
 
 
Duravelo-2, NCT06225596: Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2/3
956
US, RoW
BT8009, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin, Avelumab
BicycleTx Limited
Metastatic Urothelial Cancer
12/30
12/30
NCT06123884: BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer

Not yet recruiting
2/3
526
RoW
Recombinant humanized anti-PD-1 monoclonal antibody injection, BAT1308 injection, Cisplatin, Shunbo, Bevacizumab Injection, Pobevcy, carboplatin, Bobei, Paclitaxel for Injection, Tesu
Bio-Thera Solutions
Cervical Cancer
04/24
08/24
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2/3
840
Japan, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
AbbVie
Non-Small Cell Lung Cancer
10/31
10/31
BFAST, NCT03178552 / 2017-000076-28: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Checkmark Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Hourglass Apr 2021 - Jun 2021 : First-patient-in for cohort F of P2/3 B-FAST trial for NSCLC
Recruiting
2/3
1000
Europe, Canada, Japan, US, RoW
Alectinib, RO5424802, Atezolizumab, RO5541267, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, RO7102122, Cobimetinib, RO5514041, Vemurafenib, RO5185426, Bevacizumab, RO4876646, GDC-6036, RO7435846, Docetaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
08/28
08/28
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/24
12/25
DUBHE-N-302, NCT05576272: A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Active, not recruiting
2/3
460
RoW
QL1706, Carrelizumab, Gemcitabine, Cisplatin
Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
12/24
12/24
NCT05065957: Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Recruiting
2/3
180
RoW
D07001-softgel capsules + Xeloda (or TS-1), Treatment group, mFOLFOX, Control group
InnoPharmax Inc.
Biliary Tract Cancer
07/26
12/26
SKYSCRAPER-06, NCT04619797 / 2020-002851-39: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-06 trial in combination with Tecentriq for advanced non squamous NSCLC
Active, not recruiting
2/3
542
Europe, Canada, Japan, US, RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
05/27
05/27
KRYSTAL-7, NCT04613596 / 2020-003101-58: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation

Hourglass Jul 2023 - Dec 2023 : Data from KRYSTAL-7 trial in combination with pembrolizumab for advanced NSCLC
Checkmark Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Dec 2022 - Dec 2022: Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Recruiting
2/3
806
Europe, Canada, US, RoW
Adagrasib, Pembrolizumab, Pemrolizumab
Mirati Therapeutics Inc.
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
10/28
10/29
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
RAINBO, NCT05255653: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

Recruiting
2/3
1615
Europe, Canada
Olaparib, Lynparza, Pelvic external beam radiotherapy, EBRT, Chemotherapy, Cisplatin, Carboplatin, Paclitaxel, Durvalumab, Imfinzi, Medroxyprogesterone Acetate, Progestogen, Megestrol Acetate, Vaginal brachytherapy, Observation
Leiden University Medical Center, Institute Gustave Roussy (sponsor p53abn-RED trial), Leiden University Medical center (sponsor MMRd-GREEN trial), University College London (sponsor NSMP-ORANGE trial), Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial), Dutch Gynaecological Oncology Group, Comprehensive Cancer Centre The Netherlands, Cancer Research UK & UCL Cancer Trials Centre, Dutch Cancer Society, AstraZeneca, National Cancer Institute, France, Canadian Institutes of Health Research (CIHR)
Endometrial Cancer
01/30
01/31
 

Download Options